<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513476585</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513476585</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Haisa</surname><given-names>Minoru</given-names></name>
<xref ref-type="corresp" rid="corresp1-0300060513476585"/>
</contrib>
</contrib-group>
<aff id="aff1-0300060513476585">Department of Surgery, Okayama City Hospital, Okayama, Japan</aff>
<author-notes>
<corresp id="corresp1-0300060513476585">Dr. Minoru Haisa, Department of Surgery, Okayama City Hospital, 6–10 Kita-Ku Amase, Okayama, Japan. Email: <email>mhaisa@mvi.biglobe.ne.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>2</issue>
<fpage>253</fpage>
<lpage>264</lpage>
<history>
<date date-type="received"><day>4</day><month>11</month><year>2012</year></date>
<date date-type="accepted"><day>2</day><month>12</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Type 1 insulin-like growth factor receptor (IGF1R) signalling plays a critical role in normal cell growth, and in cancer development and progression. IGF1R and the insulin-like growth factors 1 and 2 (IGF1 and IGF2) are involved in various aspects of the malignant phenotype, suggesting that IGF1R is a potential target for cancer therapy. IGF1R is particularly important in the establishment and maintenance of the transformed phenotype, in mediating proliferation, and for the survival of tumour cells with anchorage-independent growth. IGF1R also exerts antiapoptotic activity and has a substantial influence on the control of the cell and body size. This property enables transformed cells to form macroscopic tumours and to survive the process of detachment required for metastasis. Pharmaceutical companies are investigating molecules that target IGF1R, including specific low molecular weight tyrosine kinase inhibitors and monoclonal antibodies, both of which possess various advantages and display different activity profiles. This review article focuses on the preclinical and clinical development of low molecular weight IGF1R tyrosine kinase inhibitors. It is critical to pursue a thorough molecular analysis of the metabolic activity of IGF1R to avoid possible side-effects of its inhibition.</p>
</abstract>
<kwd-group>
<kwd>IGF1</kwd>
<kwd>IGF1R</kwd>
<kwd>tyrosine kinase inhibitor</kwd>
<kwd>cancer</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513476585" sec-type="intro"><title>Introduction</title>
<p>Cell growth and proliferation are regulated by complex signalling systems involving intrinsic factors and external stimuli. Insulin-like growth factors (IGFs) and their receptors comprise a signalling system required for G<sub>1</sub>/S phase cell-cycle progression and cell division.<sup><xref ref-type="bibr" rid="bibr1-0300060513476585">1</xref></sup> The IGF system includes three ligands – IGF1, IGF2 and insulin – that interact with type 1 insulin-like growth factor receptor (IGF1R),<sup><xref ref-type="bibr" rid="bibr2-0300060513476585">2</xref></sup> IGFR2 and the insulin receptor (IR).<sup><xref ref-type="bibr" rid="bibr3-0300060513476585">3</xref></sup> IGF1R is an attractive target for cancer therapy as its abnormal expression is associated with tumourigenesis, metastasis and treatment resistance.<sup><xref ref-type="bibr" rid="bibr4-0300060513476585">4</xref></sup> Various strategies have been used to target IGFR1 in animal and human tumour cell lines and animal models, some of which may be advancing to clinical use.<sup><xref ref-type="bibr" rid="bibr5-0300060513476585">5</xref></sup> The three main approaches are receptor blockade with monoclonal antibodies, tyrosine kinase inhibition, and ligand neutralization via monoclonal antibodies targeted to ligand or recombinant IGF binding proteins (IGFBPs).<sup><xref ref-type="bibr" rid="bibr6-0300060513476585">6</xref></sup> Monoclonal antibodies directed against IGF1R cannot block the binding of both IGF1 and IGF2, nor can they downregulate both IGF1R homoreceptor and hybrid receptor pairs.<sup><xref ref-type="bibr" rid="bibr7-0300060513476585">7</xref></sup> Tyrosine kinase inhibitors indiscriminately inhibit the kinase domains of all IGF system receptors, however.<sup><xref ref-type="bibr" rid="bibr8-0300060513476585">8</xref></sup> This review will focus on the role of the IGF1R signalling pathway in cancer, and the preclinical tyrosine kinase inhibitor data that will likely guide the future development of such therapy.</p>
</sec>
<sec id="sec2-0300060513476585"><title>IGF1R signalling pathway</title>
<sec id="sec3-0300060513476585"><title>System components</title>
<sec id="sec4-0300060513476585"><title>Homoreceptors</title>
<p>The tetrameric transmembrane receptor tyrosine kinase IGF1R was identified in 1986.<sup><xref ref-type="bibr" rid="bibr2-0300060513476585">2</xref></sup> In humans, it is encoded by the <italic>IGF1R</italic> gene, which contains an open reading frame of 4101 nucleotides encoding a 1367 amino acid protein.<sup><xref ref-type="bibr" rid="bibr9-0300060513476585">9</xref></sup> IGF1R is synthesized as a single chain pre-propeptide, with a 30-amino acid signal peptide that is cleaved after translation of the nascent polypeptide chain. The propeptide is then glycosylated, dimerized, and transported to the Golgi where it is processed at a furin cleavage site, yielding α- and β-subunits.<sup><xref ref-type="bibr" rid="bibr2-0300060513476585">2</xref>,<xref ref-type="bibr" rid="bibr10-0300060513476585">10</xref></sup> The mature membrane-bound IGF1R is composed of two extracellular 130 kDa α-chains responsible for ligand binding, and two 98 kDa β-chains, comprising a transmembrane domain and a cytoplasmic tyrosine kinase domain, formed of several α–α and α–β disulphide bridges.<sup><xref ref-type="bibr" rid="bibr11-0300060513476585">11</xref></sup> The α- and β-subunits contain 11 and five potential N-linked glycosylation sites (required for IGF1R translocation to the cell surface), respectively.<sup><xref ref-type="bibr" rid="bibr12-0300060513476585">12</xref></sup> IGF1R is transported to the cell membrane as a fully assembled dimer.<sup><xref ref-type="bibr" rid="bibr13-0300060513476585">13</xref></sup></p>
<p>The intracellular domain of the β-subunit includes a binding site for phosphorylated substrates at Tyr<sup>950</sup> with a role in signal transmission, a tyrosine kinase domain with an ATP-binding site at lysine<sup>1003</sup>, three critical tyrosines at positions 1131, 1135 and 1136, and a C-terminal domain containing several phosphorylated tyrosine and serine residues (such as Tyr<sup>1250</sup>, Tyr<sup>1251</sup>, Tyr<sup>1316</sup> and Ser<sup>1280–1283</sup>) that play roles in IGF1R signalling.<sup><xref ref-type="bibr" rid="bibr14-0300060513476585">14</xref></sup></p>
</sec>
<sec id="sec5-0300060513476585"><title>Hybrid receptors</title>
<p>Both IR and IGF1R evolved from the same receptor concerned with the regulation of longevity, metabolism and organism size.<sup><xref ref-type="bibr" rid="bibr15-0300060513476585">15</xref></sup> Since IGF1R is highly homologous to the IR, sharing 84% amino acid identity in the kinase domain and near absolute conservation in the ATP binding pocket,<sup><xref ref-type="bibr" rid="bibr16-0300060513476585">16</xref></sup> IR and IGFR proreceptors may heterodimerize to form insulin–IGF hybrid receptors, comprising one α-subunit and one β-subunit each of the IR and IGF1R.<sup><xref ref-type="bibr" rid="bibr17-0300060513476585">17</xref>–<xref ref-type="bibr" rid="bibr20-0300060513476585">20</xref></sup> Further complexity arises from the existence of two isoforms of the IR, IR-A and IR-B, each of which can associate with IGF1R to form IR-A/IGF1R and IR-B/IGF1R hybrids. IR-B/IGF1R hybrids have a higher affinity for IGF1, whereas IR-A/IGF1R hybrids have equal affinity for IGF2 and insulin.<sup><xref ref-type="bibr" rid="bibr20-0300060513476585">20</xref></sup> These hybrid heterodimeric receptors could play a role in receptor signalling in normal and abnormal tissues.<sup><xref ref-type="bibr" rid="bibr21-0300060513476585">21</xref></sup> Research in the human breast cancer cell line MDA-MB157 showed that autophosphorylation of IR/IGF1R hybrid receptors in response to IGF1 exceeded that of IGF1R homoreceptors and led to increased cell proliferation, indicating that hybrid receptors were the major mediators of IGF signalling in these cells.<sup><xref ref-type="bibr" rid="bibr21-0300060513476585">21</xref></sup></p>
</sec>
<sec id="sec6-0300060513476585"><title>Ligands</title>
<p>The mitogenic and antiapoptotic effects of IGF1 and IGF2 are mediated by IGF1R.<sup><xref ref-type="bibr" rid="bibr22-0300060513476585">22</xref></sup> IGF1 and IGF2 are produced by the liver and by extrahepatic sites including tumour cells and stromal fibroblasts.<sup><xref ref-type="bibr" rid="bibr23-0300060513476585">23</xref></sup> IGFs are single chain polypeptides, comprising A-, B-, C- and D-domains, with high affinity binding to IGF1R being localized to the C-domain. The absence of Thr<sup>A8</sup>, IleA<sup>10</sup>, His<sup>B5</sup> and Tyr<sup>B16</sup> contact points in the A- and B-domains of the IR may be responsible for the weak binding affinities of IGF1 and IGF2 for the insulin receptor.<sup><xref ref-type="bibr" rid="bibr24-0300060513476585">24</xref></sup> IGF1 and IGF2 share a 62% homology in amino acid sequence, with a 40% homology between the IGFs and proinsulin.<sup><xref ref-type="bibr" rid="bibr25-0300060513476585">25</xref></sup> The binding affinity for IGF1R varies under different experimental conditions and cell types.<sup><xref ref-type="bibr" rid="bibr26-0300060513476585">26</xref></sup> Relative concentrations of IGF1 and IGF2 also vary, with IGF2 concentrations being five times higher than IGF1 levels in human foetuses, and 3.5 times higher in adult sera.<sup><xref ref-type="bibr" rid="bibr27-0300060513476585">27</xref></sup></p>
<p>Also present in the cellular microenvironment are six IGF binding proteins (IGFBP1–6) that regulate the bioavailability of IGFs by competing with IGFRs, and IGFBP proteases that modulate the balance between IGFs and IGFBPs.<sup><xref ref-type="bibr" rid="bibr28-0300060513476585">28</xref></sup> IGFBPs and IGFs comprise a major superfamily of protein hormones that regulate mitogenesis, differentiation, survival and other IGF-stimulated events in both normal and cancerous cells.<sup><xref ref-type="bibr" rid="bibr29-0300060513476585">29</xref>,<xref ref-type="bibr" rid="bibr30-0300060513476585">30</xref></sup> An in vivo study indicated that IGFBP3 inhibits the growth of HER2-overexpressing breast tumours and potentiates herceptin activity.<sup><xref ref-type="bibr" rid="bibr31-0300060513476585">31</xref></sup> Others have found, however, that high IGFBP2 expression was not associated with reduced cell proliferation in breast cancer, glioblastoma or prostate cancer.<sup><xref ref-type="bibr" rid="bibr32-0300060513476585">32</xref>–<xref ref-type="bibr" rid="bibr34-0300060513476585">34</xref></sup> These data suggest that IGFBPs can affect cell function in an independent manner, but their role in cancer is not yet clear.<sup><xref ref-type="bibr" rid="bibr35-0300060513476585">35</xref></sup></p>
</sec>
<sec id="sec7-0300060513476585"><title>IGF1R signal transduction</title>
<p>The binding of IGF1, IGF2 or insulin to IGF1R leads to the autophosphorylation of tyrosines 1131, 1135 and 1136 in the kinase domain on the intracellular portion of the β-subunits, inducing the phosphorylation of juxtamembrane tyrosines and carboxyl-terminal serines.<sup><xref ref-type="bibr" rid="bibr36-0300060513476585">36</xref></sup> Subsequently, the juxtamembrane Tyr<sup>950</sup> serves as a binding site for docking proteins including IR substrates 1–4 (IRS1–IRS4), and Src homology/collagen domain protein (SHC). These substrates initiate the PI3K/Akt (phosphatidylinositol 3-kinase/protein kinase B) and RAS/RAF/MEK/ERK signalling pathways, transmitting the IGF1R signal.<sup><xref ref-type="bibr" rid="bibr37-0300060513476585">37</xref></sup></p>
<p>Phosphorylated IRS1 recruits the regulatory and catalytic subunits of PI3K, ultimately resulting in the downstream phosphorylation of Akt at Thr<sup>308</sup>.<sup><xref ref-type="bibr" rid="bibr38-0300060513476585">38</xref>,<xref ref-type="bibr" rid="bibr39-0300060513476585">39</xref></sup> It is well known that Akt plays a critical role in controlling survival and apoptosis.<sup><xref ref-type="bibr" rid="bibr39-0300060513476585">39</xref></sup> Akt phosphorylation enhances the protein synthesis required for cell proliferation via the mammalian target of rapamycin complex, triggers the antiapoptotic effects of IGF1R through the phosphorylation and inactivation of Bcl-xL/Bcl-2 associated death promoter and the inactivation of caspase 9, and also stimulates cell growth through the inhibitory phosphorylation of growth factors (including forkhead box proteins, p21, p27, Chk1, and glycogen synthase kinase 3 [GSK3]).<sup><xref ref-type="bibr" rid="bibr38-0300060513476585">38</xref></sup></p>
<p>In parallel to PI3K-driven signalling, the recruitment of growth factor receptor-bound protein 2 (Grb2)/SOS by either phosphorylated IRS1 or SHC leads to IGF1R signal transmission via the RAS/RAF/MEK/ERK pathway.<sup><xref ref-type="bibr" rid="bibr40-0300060513476585">40</xref></sup> The Grb2/SOS complex activates the signalling pathway, resulting in the downstream phosphorylation and activation of MKK and ERK.<sup><xref ref-type="bibr" rid="bibr41-0300060513476585">41</xref></sup> Activated ERK induces cell proliferation by the phosphorylation of nuclear transcription factors such as Ets-like transcription factor-1 (Elk-1) and c-Fos.<sup><xref ref-type="bibr" rid="bibr42-0300060513476585">42</xref></sup> Activated MKK phosphorylates p38, and is responsible for inducing cell proliferation via the activation of c-Myc, JNK, and subsequently c-Jun.<sup><xref ref-type="bibr" rid="bibr43-0300060513476585">43</xref></sup></p>
<p>Cell-cycle progression is positively regulated by IGF1R signalling through cycle checkpoints in several phases. It increases ribosome activity through activation of p70S6K and S6 to facilitate the transition from G<sub>0</sub> to G<sub>1</sub>,<sup><xref ref-type="bibr" rid="bibr44-0300060513476585">44</xref></sup> increases the expression of cyclin D<sub>1</sub> to facilitate the G<sub>1</sub>/S transition<sup><xref ref-type="bibr" rid="bibr45-0300060513476585">45</xref></sup> and may increase cyclins A and B and cdc2 synthesis to promote the G<sub>2</sub>/M transition.<sup><xref ref-type="bibr" rid="bibr46-0300060513476585">46</xref></sup> The major direct effect of the IGF1R mediated signal is most likely exerted at the G<sub>1</sub>/S interface, however.<sup><xref ref-type="bibr" rid="bibr47-0300060513476585">47</xref></sup></p>
</sec>
</sec>
</sec>
<sec id="sec8-0300060513476585"><title>IGF1R: A target for cancer therapy</title>
<p>Emerging evidence implicates IGF1R signalling in the development and progression of cancer. IGF1R, IGF1 and IGF2 are involved in various aspects of the malignant phenotype, suggesting that IGF1R may be a target for cancer therapy.</p>
<sec id="sec9-0300060513476585"><title>IGF1R signalling in normal physiology</title>
<p>It is known that IGF1R protects cells from apoptosis, while promoting proliferation and cell growth. Newborn mice lacking IGF1 or IGF2 were found to be significantly smaller (60% of normal birth weight) than wild-type mice, and IGF1R knockout mice were even smaller (45% of normal size), confirming that IGF and its receptor play a role in normal growth.<sup><xref ref-type="bibr" rid="bibr48-0300060513476585">48</xref></sup> Mice with double IR/IGF1R deficiency in both cardiac and skeletal muscle die early from heart failure, due to the co-ordinated effects of IR/IGF1R on the downregulation of electron transport and mitochondrial fatty acid β-oxidation.<sup><xref ref-type="bibr" rid="bibr49-0300060513476585">49</xref></sup> IGF signalling from these receptors is therefore essential for normal cardiac metabolism and function. IGF1R also plays a role in embryonic bone development.<sup><xref ref-type="bibr" rid="bibr50-0300060513476585">50</xref></sup> Studies of IGF1R signalling in the nervous system have shown that IGF signalling promotes differentiation and proliferation, and sustains survival by preventing apoptosis of neuronal and brain derived cells in vitro.<sup><xref ref-type="bibr" rid="bibr51-0300060513476585">51</xref></sup> Other studies have shown that IGF1R regulates cell lifespan, adhesion and motility, and can induce differentiation in specific cellular contexts.<sup><xref ref-type="bibr" rid="bibr52-0300060513476585">52</xref></sup> The role of IGF1R in normal physiology appears to be more complex than was thought when this protein was initially identified.</p>
</sec>
<sec id="sec10-0300060513476585"><title>IGF-IR signalling in malignancy</title>
<p>It has been shown that IGF1R, its ligands and IGFBPs are highly expressed in prostate,<sup><xref ref-type="bibr" rid="bibr53-0300060513476585">53</xref></sup> breast,<sup><xref ref-type="bibr" rid="bibr54-0300060513476585">54</xref></sup> colorectal<sup><xref ref-type="bibr" rid="bibr55-0300060513476585">55</xref></sup> and pancreatic cancers,<sup><xref ref-type="bibr" rid="bibr56-0300060513476585">56</xref></sup> melanoma,<sup><xref ref-type="bibr" rid="bibr57-0300060513476585">57</xref></sup> multiple myeloma,<sup><xref ref-type="bibr" rid="bibr58-0300060513476585">58</xref></sup> mesothelioma,<sup><xref ref-type="bibr" rid="bibr59-0300060513476585">59</xref></sup> glioblastoma<sup><xref ref-type="bibr" rid="bibr60-0300060513476585">60</xref></sup> and childhood malignancies.<sup><xref ref-type="bibr" rid="bibr27-0300060513476585">27</xref></sup> IGFs and IGF1R regulate all aspects of the malignant phenotype.<sup><xref ref-type="bibr" rid="bibr61-0300060513476585">61</xref></sup></p>
<p>Studies show a correlation between circulating IGF1 levels and cancer risk in some malignancies (premenopausal breast, prostate and colorectal carcinomas, as well as lung, endometrial and bladder cancers).<sup><xref ref-type="bibr" rid="bibr28-0300060513476585">28</xref></sup> Individuals with high serum IGF1 concentrations and/or lower levels of IGFBPs had more than twice the risk of developing cancer than those at the low end of the normal range.<sup><xref ref-type="bibr" rid="bibr61-0300060513476585">61</xref></sup> Other studies have failed to indicate consistent correlations, for example circulating IGF1, IGFBP1, IGFBP3 and growth hormone levels were found to have no association with breast cancer risk in a large cohort of premenopausal women.<sup><xref ref-type="bibr" rid="bibr62-0300060513476585">62</xref></sup></p>
<p>Type 1 insulin-like growth factor receptor plays an important role in the establishment and maintenance of the transformed phenotype. It is not unique in driving tumour cell proliferation, but is essential in the mediation of proliferation and survival of tumour cells with anchorage-independent growth.<sup><xref ref-type="bibr" rid="bibr63-0300060513476585">63</xref></sup> IGF1R also exerts antiapoptotic activity and has a significant influence on the control of cell and body size.<sup><xref ref-type="bibr" rid="bibr63-0300060513476585">63</xref></sup> This property enables transformed cells to form macroscopic tumours, and to survive the process of detachment that is required for metastasis.<sup><xref ref-type="bibr" rid="bibr64-0300060513476585">64</xref></sup> Data from in vitro and in vivo studies have confirmed the importance of the IGF1R system in cancer growth and metastasis. Treatment of synovial sarcoma cell lines with the IGF1R antagonist NVP-AEW541 led to increased apoptosis, and impaired growth, mitotic activity and cell migration.<sup><xref ref-type="bibr" rid="bibr65-0300060513476585">65</xref></sup> IGF1R did not enhance motility in LCC6-DN cells (a breast cancer cell line with dominant negative IGF1R), in contrast to increased motility in wild-type LCC6 cells, suggesting that metastasis is inhibited by truncated IGF1R.<sup><xref ref-type="bibr" rid="bibr66-0300060513476585">66</xref></sup> The injection of mice with LCC6, but not LCC6-DN, cells resulted in the formation of lung metastases, indicating that IGF1R regulates metastasis independently from tumour growth.<sup><xref ref-type="bibr" rid="bibr66-0300060513476585">66</xref></sup> Using a similar approach, human KM12L4 colon cancer xenograft tumours induced in nude mice were significantly smaller when the KM12L4 cells were transfected with a truncated dominant-negative form of IGF1R than when using wild-type cells.<sup><xref ref-type="bibr" rid="bibr67-0300060513476585">67</xref></sup> In addition, the colon cancer cells with dominant negative IGF1R failed to produce liver metastases after splenic injection.<sup><xref ref-type="bibr" rid="bibr67-0300060513476585">67</xref></sup> These findings suggest that IGF1R plays an important role in the metastasis of cancer cells.</p>
<p>Type 1 insulin-like growth factor mediates proliferation, motility and apoptosis protection in cancer, and represents a promising target for cancer therapy. Clinical trials are required to examine this treatment potential fully.</p>
</sec>
</sec>
<sec id="sec11-0300060513476585"><title>Targeting the IGF system for cancer therapy</title>
<p>The critical role of IGF signalling in initiating and promoting tumour progression has resulted in it becoming an attractive target for cancer therapy. Various strategies have been used to target components of this system both in vitro and in vivo, some of which have advanced to clinical use.<sup><xref ref-type="bibr" rid="bibr4-0300060513476585">4</xref></sup> The general aim of these approaches is to interfere with the function of IGF system components by methods including small interfering RNA, antisense oligonucleotides, antisense RNA, triple helix-forming oligodeoxynucleotides, specific kinase inhibitors, single chain antibodies and fully humanized anti-IGF1R monoclonal antibodies.<sup><xref ref-type="bibr" rid="bibr4-0300060513476585">4</xref></sup> The neutralization of natural ligands can also inhibit IGF1R activation. There are three ways to neutralize IGF action: the overexpression of IGF2R<sup><xref ref-type="bibr" rid="bibr68-0300060513476585">68</xref></sup> and IGFBP1<sup>69</sup>; the use of soluble IGF1R (e.g. IGF1R<sup>933</sup>);<sup><xref ref-type="bibr" rid="bibr70-0300060513476585">70</xref></sup> and antibodies against IGF2 and IGF2 (such as the rat monoclonal antibody, KM1468).<sup><xref ref-type="bibr" rid="bibr71-0300060513476585">71</xref></sup> These studies demonstrated that functional interference of IGF1R leads to the inhibition of cancer cell proliferation, survival, anchorage-independent growth in vitro, tumour growth and metastasis, and sensitizes cancer cells to various kinds of radiation and chemotherapeutic regimens in vivo.</p>
</sec>
<sec id="sec12-0300060513476585"><title>IGF1R tyrosine kinase inhibitors</title>
<p>The two most thoroughly investigated strategies for IGF1R inhibition are small-molecule tyrosine kinase inhibitors and monoclonal antibodies, both of which have various advantages and display different activity profiles. Studies have concentrated on modulating IGF1R tyrosine kinase activity by targeting its intracellular kinase domain. The high sequence homology of the kinase domains of IGF1R and IR<sup><xref ref-type="bibr" rid="bibr2-0300060513476585">2</xref></sup> has complicated the design process for an IGF1R specific low-molecular weight tyrosine kinase inhibitor. <xref ref-type="table" rid="table1-0300060513476585">Table 1</xref> lists nine IGFR1 kinase-specific inhibitors at different stages of development.<sup><xref ref-type="bibr" rid="bibr72-0300060513476585">72</xref></sup>
<table-wrap id="table1-0300060513476585" position="float"><label>Table 1.</label><caption><p>Class and trial status of type 1 insulin-like growth factor receptor (IGFR1) tyrosine kinase inhibitors currently under developmen.</p></caption>
<graphic alternate-form-of="table1-0300060513476585" xlink:href="10.1177_0300060513476585-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Drug name</th>
<th>Company</th>
<th>Class</th>
<th>Trial status</th>
</tr></thead>
<tbody align="left">
<tr>
<td>INSM-18</td>
<td>Insmed UCSF</td>
<td>Reversible ATP-competitive</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>OSI-906</td>
<td>OSI Pharmaceuticals</td>
<td>Oral small molecule Reversible ATP-competitive</td>
<td>Phase I</td>
</tr>
<tr>
<td>XL-228</td>
<td>Exelixis</td>
<td>Oral small molecule</td>
<td>Phase I</td>
</tr>
<tr>
<td>NVP-ADW742</td>
<td>Novartis</td>
<td>Reversible ATP-competitive</td>
<td>Preclinical</td>
</tr>
<tr>
<td>NVP-AEW541</td>
<td>Novartis</td>
<td>Reversible ATP-competitive</td>
<td>Preclinical</td>
</tr>
<tr>
<td>AG-1024</td>
<td>Merck</td>
<td>Non ATP-competitive</td>
<td>Preclinical</td>
</tr>
<tr>
<td>BMS-536924</td>
<td>Bristol-Myers Squibb</td>
<td>ATP-competitive</td>
<td>Preclinical</td>
</tr>
<tr>
<td>BMS-554417</td>
<td>Bristol-Myers Squibb</td>
<td>Oral small molecule Reversible ATP-competitive</td>
<td>Preclinical</td>
</tr>
<tr>
<td>BVP-51004 (Cyclolignan PPP)</td>
<td>Karolinska Cancer Institute Biovitrum</td>
<td>Oral small molecule Non ATP-competitive</td>
<td>Preclinical</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<p>Small-molecule tyrosine kinase inhibitors can be given orally and are able to cross the blood–brain barrier, but may result in drug–drug interactions or overlapping toxicities when used in combination with other agents.<sup><xref ref-type="bibr" rid="bibr73-0300060513476585">73</xref></sup> In addition, small-molecule tyrosine kinase inhibitors may be associated with more serious metabolic adverse effects than monoclonal antibodies, as they can affect both IR and IGF1R signalling.<sup><xref ref-type="bibr" rid="bibr74-0300060513476585">74</xref></sup> An advantage of small-molecule IGF1R tyrosine kinase inhibitors over antibodies is their wider range of inhibition due to the frequent expression of IR in tumours, hyperinsulinism in aggressive cancers, and IR-mediated resistance to IGF1R-targeted therapy, all of which may enhance antineoplastic activity.<sup><xref ref-type="bibr" rid="bibr75-0300060513476585">75</xref></sup></p>
<p>Combination therapy with either cytotoxic (chemotherapy or radiation) or cytostatic treatments and tyrosine kinase inhibitors has been shown to increase the effect of inhibitors, as IGF1R is closely associated with apoptosis, cell survival and radiation, and chemotherapy resistance. For example, combination treatment with the IGFR1 tyrosine kinase inhibitor NVP-AEW541 and cytostatics such as doxorubicin or fluvastatin resulted in additive antineoplastic effects in gastrointestinal neuroendocrine tumour (NET) cells.<sup><xref ref-type="bibr" rid="bibr76-0300060513476585">76</xref></sup> In addition, NVP-AEW541 in combination with IGFBP3 abrogated IGF1 responses at 10-fold lower doses than either compound alone in human head and neck squamous cell carcinoma (HNSCC).<sup><xref ref-type="bibr" rid="bibr77-0300060513476585">77</xref></sup> These findings suggest that combination treatment may be a promising approach in IGF1R targeted therapy, but this requires further investigation.</p>
<p>There are two categories of IGF1R tyrosine kinase inhibitor. The most common are ATP antagonists (INSM-18, OSI-906, NVP-ADW742, NVP-AEW541, BMS-536924 and BMS-554417), with non-ATP antagonists also under development (BVP-51004 [PPP] and AG-1024). In vitro pharmacological studies have found variations in the selectivity of these molecules for IGF1R over IR. OSI-906, INSM-18, picropodophylin and NVP-AEW541 appear to be more selective for IGF1R, and BMS-554417 has equivalent potency towards both receptors. The different selectivity for each receptor defines a specific therapeutic opportunity for each drug.</p>
<sec id="sec13-0300060513476585"><title>INSM-18</title>
<p>The orally available molecule INSM-18 directly inhibits the human epidermal growth factor receptor c-erbB2/HER2/neu and IGF1R tyrosine kinase.<sup><xref ref-type="bibr" rid="bibr72-0300060513476585">72</xref></sup> INSM-18 was discovered by the University of California, San Francisco and is currently being developed with Insmed (Monmouth Junction, NJ, USA). Its IGF1R inhibitory mechanism is unclear. INSM-18 may also induce apoptosis, inhibit arachidonic acid 5-lipoxygenase and prevent the release of reactive oxygen species.<sup><xref ref-type="bibr" rid="bibr72-0300060513476585">72</xref></sup> The antitumour activity of INSM-18 has been demonstrated in breast, lung, pancreatic and prostate tumour preclinical studies.<sup><xref ref-type="bibr" rid="bibr72-0300060513476585">72</xref></sup> INSM-18 had a good safety profile and was well tolerated in two single-dose phase I clinical studies in healthy volunteers.<sup><xref ref-type="bibr" rid="bibr72-0300060513476585">72</xref></sup> A dose-escalating phase I/II clinical study has been completed by the University of California, the results of which will be used to design a phase II clinical study.<sup><xref ref-type="bibr" rid="bibr72-0300060513476585">72</xref></sup></p>
</sec>
<sec id="sec14-0300060513476585"><title>NVP-AEW541</title>
<p>The low molecular weight molecule NVP-AEW541 is a pyrrolo[2,3-d]pyrimidine derived kinase inhibitor with a higher selectivity for IGF1R (50% inhibitory concentration [IC<sub>50</sub>] 0.086 µM) than IR (IC<sub>50</sub> 2.3 µM) in cellular assays.<sup><xref ref-type="bibr" rid="bibr78-0300060513476585">78</xref></sup> Preclinical studies are ongoing, but its antitumour activity has been demonstrated in musculoskeletal tumours,<sup><xref ref-type="bibr" rid="bibr79-0300060513476585">79</xref></sup> hepatocellular carcinoma,<sup><xref ref-type="bibr" rid="bibr80-0300060513476585">80</xref></sup> NET,<sup><xref ref-type="bibr" rid="bibr76-0300060513476585">76</xref></sup> malignant mesothelioma,<sup><xref ref-type="bibr" rid="bibr81-0300060513476585">81</xref></sup> HNSCC,<sup><xref ref-type="bibr" rid="bibr77-0300060513476585">77</xref></sup> colorectal cancer,<sup><xref ref-type="bibr" rid="bibr82-0300060513476585">82</xref></sup> neuroblastoma,<sup><xref ref-type="bibr" rid="bibr83-0300060513476585">83</xref></sup> Ewing's sarcoma,<sup><xref ref-type="bibr" rid="bibr84-0300060513476585">84</xref></sup> multiple myeloma,<sup><xref ref-type="bibr" rid="bibr85-0300060513476585">85</xref></sup> pancreatic cancer,<sup><xref ref-type="bibr" rid="bibr86-0300060513476585">86</xref></sup> gastrointestinal stromal tumour,<sup><xref ref-type="bibr" rid="bibr87-0300060513476585">87</xref></sup> gastrointestinal cancer,<sup><xref ref-type="bibr" rid="bibr88-0300060513476585">88</xref></sup> breast cancer<sup><xref ref-type="bibr" rid="bibr89-0300060513476585">89</xref></sup> and synovial sarcoma.<sup><xref ref-type="bibr" rid="bibr65-0300060513476585">65</xref></sup> As expected for a specific IGF1R kinase inhibitor, NVP-AEW541 abrogated IGF1-mediated survival, inhibited the proliferation of cultured tumour cell lines by inducing apoptosis and cell cycle arrest in vitro, and significantly inhibited the growth of tumour xenografts in vivo.<sup><xref ref-type="bibr" rid="bibr65-0300060513476585">65</xref>,<xref ref-type="bibr" rid="bibr76-0300060513476585">76</xref>,<xref ref-type="bibr" rid="bibr77-0300060513476585">77</xref>,<xref ref-type="bibr" rid="bibr79-0300060513476585">79</xref>–<xref ref-type="bibr" rid="bibr89-0300060513476585">89</xref></sup> Accumulating evidence suggests that NVP-AEW541 represents a potential therapeutic strategy for the treatment of tumour types in which IGF1R-mediated signalling is required for driving/survival.</p>
</sec>
<sec id="sec15-0300060513476585"><title>BVP-51004</title>
<p>The non ATP antagonist BVP-51004 (cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo [1,5-a]pyrazin-8-ylamine, also known as PPP and PQIP) was originally identified at the Karolinska Cancer Institute (Sweden) and is currently being developed by Swedish Orphan Biovitrum (Stockholm, Sweden). BVP-51004 inhibits IGF1R autophosphorylation with 14-fold selectivity relative to IR, via inhibition of the phosphorylation of Tyr<sup>1136</sup> in the kinase activation loop, stabilizing the activation loop conformation.<sup><xref ref-type="bibr" rid="bibr90-0300060513476585">90</xref>,<xref ref-type="bibr" rid="bibr91-0300060513476585">91</xref></sup> It has been demonstrated that BVP-51004 preferentially inhibits the PI3K-Akt pathway, and blocks the growth of a variety of tumours, both in vitro and in vivo.<sup><xref ref-type="bibr" rid="bibr92-0300060513476585">92</xref></sup> A study in human colorectal cancer cells indicated that BVP-51004 is a selective IGF1R kinase inhibitor that is highly effective in IGF2-driven tumours.<sup><xref ref-type="bibr" rid="bibr59-0300060513476585">59</xref></sup></p>
</sec>
</sec>
<sec id="sec16-0300060513476585" sec-type="conclusions"><title>Conclusions</title>
<p>Multiple lines of evidence indicate that the IGFR1 signalling system plays a critical role in carcinogenesis, and high concentrations of IGF1R and its ligands are predictive of increased cancer risk. Pharmaceutical companies are investigating candidate drugs that target IGF1R, and early clinical data are encouraging. Ongoing trials will determine the relative safety and efficacy of IGF1R tyrosine kinase inhibitors and monoclonal antibodies. Research is required to identify the most rational combination therapies, which may also provide information for future clinical trial designs. It is critical to pursue a thorough molecular analysis of the metabolic activity of IGF1R in order to avoid possible side-effects of its inhibition.</p>
</sec>
</body>
<back>
<sec id="sec17-0300060513476585"><title>Declaration of conflicting interest</title>
<p>The author declares that there are no conflicts of interest.</p>
</sec>
<sec id="sec18-0300060513476585"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0300060513476585"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>M</given-names></name><name><surname>Dexter</surname><given-names>TM</given-names></name></person-group>. <article-title>Growth factors in development, transformation, and tumorigenesis</article-title>. <source>Cell</source> <year>1991</year>; <volume>64</volume>: <fpage>271</fpage>–<lpage>280</lpage>.</citation></ref>
<ref id="bibr2-0300060513476585"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Tam</surname><given-names>AW</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that deﬁne functional speciﬁcity</article-title>. <source>EMBO J</source> <year>1986</year>; <volume>5</volume>: <fpage>2503</fpage>–<lpage>2512</lpage>.</citation></ref>
<ref id="bibr3-0300060513476585"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belfiore</surname><given-names>A</given-names></name></person-group>. <article-title>The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer</article-title>. <source>Curr Pharm Des</source> <year>2007</year>; <volume>13</volume>: <fpage>671</fpage>–<lpage>686</lpage>.</citation></ref>
<ref id="bibr4-0300060513476585"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heidegger</surname><given-names>I</given-names></name><name><surname>Pircher</surname><given-names>A</given-names></name><name><surname>Klocker</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Targeting the insulin-like growth factor network in cancer therapy</article-title>. <source>Cancer Biol Ther</source> <year>2011</year>; <volume>11</volume>: <fpage>701</fpage>–<lpage>707</lpage>.</citation></ref>
<ref id="bibr5-0300060513476585"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>García-Echeverría</surname><given-names>C</given-names></name></person-group>. <article-title>Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer</article-title>. <source>Drug Discov Today</source> <year>2005</year>; <volume>10</volume>: <fpage>1041</fpage>–<lpage>1047</lpage>.</citation></ref>
<ref id="bibr6-0300060513476585"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnaldez</surname><given-names>FI</given-names></name><name><surname>Helman</surname><given-names>LJ</given-names></name></person-group>. <article-title>Targeting the insulin growth factor receptor 1</article-title>. <source>Hematol Oncol Clin North Am</source> <year>2012</year>; <volume>26</volume>: <fpage>527</fpage>–<lpage>542</lpage>.</citation></ref>
<ref id="bibr7-0300060513476585"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ewing</surname><given-names>GP</given-names></name><name><surname>Goff</surname><given-names>LW</given-names></name></person-group>. <article-title>The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma</article-title>. <source>Clin Colorectal Cancer</source> <year>2010</year>; <volume>9</volume>: <fpage>219</fpage>–<lpage>223</lpage>.</citation></ref>
<ref id="bibr8-0300060513476585"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>F</given-names></name></person-group>. <article-title>Receptor tyrosine kinases and targeted cancer therapeutics</article-title>. <source>Biol Pharm Bull</source> <year>2011</year>; <volume>34</volume>: <fpage>1774</fpage>–<lpage>1180</lpage>.</citation></ref>
<ref id="bibr9-0300060513476585"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeRoith</surname><given-names>D</given-names></name><name><surname>Werner</surname><given-names>H</given-names></name><name><surname>Beitner-Johnson</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Molecular and cellular aspects of the insulin-like growth factor I receptor</article-title>. <source>Endocr Rev</source> <year>1995</year>; <volume>16</volume>: <fpage>143</fpage>–<lpage>163</lpage>.</citation></ref>
<ref id="bibr10-0300060513476585"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>TE</given-names></name><name><surname>Epa</surname><given-names>VC</given-names></name><name><surname>Garrett</surname><given-names>TP</given-names></name><etal/></person-group>. <article-title>Structure and function of the type 1 insulin-like growth factor receptor</article-title>. <source>Cell Mol Life Sci</source> <year>2000</year>; <volume>57</volume>: <fpage>1050</fpage>–<lpage>1093</lpage>.</citation></ref>
<ref id="bibr11-0300060513476585"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Massagué</surname><given-names>J</given-names></name><name><surname>Czech</surname><given-names>MP</given-names></name></person-group>. <article-title>The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor</article-title>. <source>J Biol Chem</source> <year>1982</year>; <volume>257</volume>: <fpage>5038</fpage>–<lpage>5045</lpage>.</citation></ref>
<ref id="bibr12-0300060513476585"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>H</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name></person-group>. <article-title>The role of the insulin-like growth factor system in human cancer</article-title>. <source>Adv Cancer Res</source> <year>1996</year>; <volume>68</volume>: <fpage>183</fpage>–<lpage>223</lpage>.</citation></ref>
<ref id="bibr13-0300060513476585"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlberg</surname><given-names>M</given-names></name><name><surname>Dricu</surname><given-names>A</given-names></name><name><surname>Blegen</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Mevalonic acid is limiting for <italic>N</italic>-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth</article-title>. <source>J Biol Chem</source> <year>1996</year>; <volume>271</volume>: <fpage>17453</fpage>–<lpage>17462</lpage>.</citation></ref>
<ref id="bibr14-0300060513476585"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Favelyukis</surname><given-names>S</given-names></name><name><surname>Till</surname><given-names>JH</given-names></name><name><surname>Hubbard</surname><given-names>SR</given-names></name><etal/></person-group>. <article-title>Structure and autoregulation of the insulin-like growth factor 1 receptor kinase</article-title>. <source>Nat Struct Biol</source> <year>2001</year>; <volume>8</volume>: <fpage>1058</fpage>–<lpage>1063</lpage>.</citation></ref>
<ref id="bibr15-0300060513476585"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Browner</surname><given-names>WS</given-names></name><name><surname>Kahn</surname><given-names>AJ</given-names></name><name><surname>Ziv</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>The genetics of human longevity</article-title>. <source>Am J Med</source> <year>2004</year>; <volume>117</volume>: <fpage>851</fpage>–<lpage>860</lpage>.</citation></ref>
<ref id="bibr16-0300060513476585"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munshi</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>DL</given-names></name><name><surname>Kornienko</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source> <year>2003</year>; <volume>59</volume>: <fpage>1725</fpage>–<lpage>1730</lpage>.</citation></ref>
<ref id="bibr17-0300060513476585"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moxham</surname><given-names>CP</given-names></name><name><surname>Duronio</surname><given-names>V</given-names></name><name><surname>Jacobs</surname><given-names>S</given-names></name></person-group>. <article-title>Insulin-like growth factor I receptor <italic>β</italic>-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers</article-title>. <source>J Biol Chem</source> <year>1989</year>; <volume>264</volume>: <fpage>13238</fpage>–<lpage>13244</lpage>.</citation></ref>
<ref id="bibr18-0300060513476585"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soos</surname><given-names>MA</given-names></name><name><surname>Siddle</surname><given-names>K</given-names></name></person-group>. <article-title>Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors</article-title>. <source>Biochem J</source> <year>1989</year>; <volume>263</volume>: <fpage>553</fpage>–<lpage>563</lpage>.</citation></ref>
<ref id="bibr19-0300060513476585"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Treadway</surname><given-names>JL</given-names></name><name><surname>Morrison</surname><given-names>BD</given-names></name><name><surname>Goldﬁne</surname><given-names>ID</given-names></name><etal/></person-group>. <article-title>Assembly of insulin/insulin-like growth factor-1 hybrid receptors in vitro</article-title>. <source>J Biol Chem</source> <year>1989</year>; <volume>264</volume>: <fpage>21450</fpage>–<lpage>21453</lpage>.</citation></ref>
<ref id="bibr20-0300060513476585"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pandini</surname><given-names>G</given-names></name><name><surname>Frasca</surname><given-names>F</given-names></name><name><surname>Mineo</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved</article-title>. <source>J Biol Chem</source> <year>2002</year>; <volume>277</volume>: <fpage>39684</fpage>–<lpage>39695</lpage>.</citation></ref>
<ref id="bibr21-0300060513476585"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pandini</surname><given-names>G</given-names></name><name><surname>Vigneri</surname><given-names>R</given-names></name><name><surname>Costantino</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling</article-title>. <source>Clin Cancer Res</source> <year>1999</year>; <volume>5</volume>: <fpage>1935</fpage>–<lpage>1944</lpage>.</citation></ref>
<ref id="bibr22-0300060513476585"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>AM</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name></person-group>. <article-title>Control of cell survival by IGF signaling pathways</article-title>. <source>Growth Horm IGF Res</source> <year>2002</year>; <volume>12</volume>: <fpage>193</fpage>–<lpage>197</lpage>.</citation></ref>
<ref id="bibr23-0300060513476585"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YW</given-names></name><name><surname>Boyartchuk</surname><given-names>V</given-names></name><name><surname>Lewis</surname><given-names>BC</given-names></name></person-group>. <article-title>Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells</article-title>. <source>Neoplasia</source> <year>2009</year>; <volume>11</volume>: <fpage>835</fpage>–<lpage>845</lpage>.</citation></ref>
<ref id="bibr24-0300060513476585"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gauguin</surname><given-names>L</given-names></name><name><surname>Klaproth</surname><given-names>B</given-names></name><name><surname>Sajid</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Structural basis for the lower affinity of the insulin-like growth factors for the insulin receptor</article-title>. <source>J Biol Chem</source> <year>2008</year>; <volume>283</volume>: <fpage>2604</fpage>–<lpage>2613</lpage>.</citation></ref>
<ref id="bibr25-0300060513476585"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fürstenberger</surname><given-names>G</given-names></name><name><surname>Senn</surname><given-names>HJ</given-names></name></person-group>. <article-title>Insulin-like growth factors and cancer</article-title>. <source>Lancet Oncol</source> <year>2002</year>; <volume>3</volume>: <fpage>298</fpage>–<lpage>302</lpage>.</citation></ref>
<ref id="bibr26-0300060513476585"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danielsen</surname><given-names>A</given-names></name><name><surname>Larsen</surname><given-names>E</given-names></name><name><surname>Gammeltoft</surname><given-names>S</given-names></name></person-group>. <article-title>Chromaffin cells express two types of insulin-like growth factor receptors</article-title>. <source>Brain Res</source> <year>1990</year>; <volume>518</volume>: <fpage>95</fpage>–<lpage>100</lpage>.</citation></ref>
<ref id="bibr27-0300060513476585"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>DM</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Levels of insulin-like growth factors I and II in human cord blood</article-title>. <source>J Clin Endocrinol Metab</source> <year>1983</year>; <volume>57</volume>: <fpage>609</fpage>–<lpage>612</lpage>.</citation></ref>
<ref id="bibr28-0300060513476585"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalus</surname><given-names>W</given-names></name><name><surname>Zweckstetter</surname><given-names>M</given-names></name><name><surname>Renner</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions</article-title>. <source>EMBO J</source> <year>1998</year>; <volume>17</volume>: <fpage>6558</fpage>–<lpage>6572</lpage>.</citation></ref>
<ref id="bibr29-0300060513476585"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Firth</surname><given-names>SM</given-names></name><name><surname>Baxter</surname><given-names>RC</given-names></name></person-group>. <article-title>Cellular actions of the insulin-like growth factor binding proteins</article-title>. <source>Endocr Rev</source> <year>2002</year>; <volume>23</volume>: <fpage>824</fpage>–<lpage>854</lpage>.</citation></ref>
<ref id="bibr30-0300060513476585"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sitar</surname><given-names>T</given-names></name><name><surname>Popowicz</surname><given-names>GM</given-names></name><name><surname>Siwanowicz</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins</article-title>. <source>Proc Natl Acad Sci USA</source> <year>2006</year>; <volume>103</volume>: <fpage>13028</fpage>–<lpage>13033</lpage>.</citation></ref>
<ref id="bibr31-0300060513476585"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jerome</surname><given-names>L</given-names></name><name><surname>Alami</surname><given-names>N</given-names></name><name><surname>Belanger</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2–overexpressing breast tumors and potentiates Herceptin activity <italic>in vivo</italic></article-title>. <source>Cancer Res</source> <year>2006</year>; <volume>66</volume>: <fpage>7245</fpage>–<lpage>7252</lpage>.</citation></ref>
<ref id="bibr32-0300060513476585"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>AI</given-names></name><name><surname>Levitt</surname><given-names>RJ</given-names></name><name><surname>Eigl</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer</article-title>. <source>Clin Cancer Res</source> <year>2008</year>; <volume>14</volume>: <fpage>6944</fpage>–<lpage>6954</lpage>.</citation></ref>
<ref id="bibr33-0300060513476585"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehrian-Shai</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>CD</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2007</year>; <volume>104</volume>: <fpage>5563</fpage>–<lpage>5568</lpage>.</citation></ref>
<ref id="bibr34-0300060513476585"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levitt</surname><given-names>RJ</given-names></name><name><surname>Georgescu</surname><given-names>MM</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name></person-group>. <article-title>PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2</article-title>. <source>Biochem Biophys Res Commun</source> <year>2005</year>; <volume>336</volume>: <fpage>1056</fpage>–<lpage>1061</lpage>.</citation></ref>
<ref id="bibr35-0300060513476585"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perks</surname><given-names>CM</given-names></name><name><surname>Holly</surname><given-names>JM</given-names></name></person-group>. <article-title>IGF binding proteins (IGFBPs) and regulation of breast cancer biology</article-title>. <source>J Mammary Gland Biol Neoplasia</source> <year>2008</year>; <volume>13</volume>: <fpage>455</fpage>–<lpage>469</lpage>.</citation></ref>
<ref id="bibr36-0300060513476585"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Pourpak</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name></person-group>. <article-title>Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach <italic>J Med Chem</italic></article-title>. <year>2009</year>; <volume>52</volume>: <fpage>4981</fpage>–<lpage>5004</lpage>.</citation></ref>
<ref id="bibr37-0300060513476585"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>JG</given-names></name><name><surname>Steelman</surname><given-names>LS</given-names></name><name><surname>White</surname><given-names>ER</given-names></name><name><surname>McCubrey</surname><given-names>JA</given-names></name></person-group>. <article-title>Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells</article-title>. <source>Cell Cycle</source> <year>2004</year>; <volume>3</volume>: <fpage>372</fpage>–<lpage>379</lpage>.</citation></ref>
<ref id="bibr38-0300060513476585"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarbassov</surname><given-names>DD</given-names></name><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</article-title>. <source>Science</source> <year>2005</year>; <volume>307</volume>: <fpage>1098</fpage>–<lpage>1101</lpage>.</citation></ref>
<ref id="bibr39-0300060513476585"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacinto</surname><given-names>E</given-names></name><name><surname>Facchinetti</surname><given-names>V</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity</article-title>. <source>Cell</source> <year>2006</year>; <volume>127</volume>: <fpage>125</fpage>–<lpage>137</lpage>.</citation></ref>
<ref id="bibr40-0300060513476585"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perrini</surname><given-names>S</given-names></name><name><surname>Laviola</surname><given-names>L</given-names></name><name><surname>Carreira</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis</article-title>. <source>J Endocrinol</source> <year>2010</year>; <volume>205</volume>: <fpage>201</fpage>–<lpage>210</lpage>.</citation></ref>
<ref id="bibr41-0300060513476585"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Water</surname><given-names>SB</given-names></name><name><surname>Holt</surname><given-names>KH</given-names></name><etal/></person-group>. <article-title>SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways</article-title>. <source>J Biol Chem</source> <year>1996</year>; <volume>271</volume>: <fpage>6328</fpage>–<lpage>6332</lpage>.</citation></ref>
<ref id="bibr42-0300060513476585"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchwalter</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>C</given-names></name><name><surname>Wasylyk</surname><given-names>B</given-names></name></person-group>. <article-title>Ets ternary complex transcription factors</article-title>. <source>Gene</source> <year>2004</year>; <volume>324</volume>: <fpage>1</fpage>–<lpage>14</lpage>.</citation></ref>
<ref id="bibr43-0300060513476585"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mittelstadt</surname><given-names>PR</given-names></name><name><surname>Salvador</surname><given-names>JM</given-names></name><name><surname>Fornace</surname><given-names>AJ</given-names><suffix>Jr</suffix></name><etal/></person-group>. <article-title>Activating p38 MAPK: new tricks for an old kinase</article-title>. <source>Cell Cycle</source> <year>2005</year>; <volume>4</volume>: <fpage>1189</fpage>–<lpage>1192</lpage>.</citation></ref>
<ref id="bibr44-0300060513476585"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sunami</surname><given-names>T</given-names></name><name><surname>Byrne</surname><given-names>N</given-names></name><name><surname>Diehl</surname><given-names>RE</given-names></name><etal/></person-group>. <article-title>Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation</article-title>. <source>J Biol Chem</source> <year>2010</year>; <volume>285</volume>: <fpage>4587</fpage>–<lpage>4594</lpage>.</citation></ref>
<ref id="bibr45-0300060513476585"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tognon</surname><given-names>CE</given-names></name><name><surname>Sorensen</surname><given-names>PH</given-names></name></person-group>. <article-title>Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy</article-title>. <source>Expert Opin Ther Targets</source> <year>2012</year>; <volume>16</volume>: <fpage>33</fpage>–<lpage>48</lpage>.</citation></ref>
<ref id="bibr46-0300060513476585"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahmoudabady</surname><given-names>M</given-names></name><name><surname>Mathieu</surname><given-names>M</given-names></name><name><surname>Touihri</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Cardiac insulin-like growth factor-1 and cyclins gene expression in canine models of ischemic or overpacing cardiomyopathy</article-title>. <source>BMC Cardiovasc Disord</source> <year>2009</year>; <volume>9</volume>: <fpage>49</fpage>–<lpage>49</lpage>.</citation></ref>
<ref id="bibr47-0300060513476585"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samani</surname><given-names>A</given-names></name><name><surname>Yakar</surname><given-names>S</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The role of the IGF system in cancer growth and metastasis: overview and recent insights</article-title>. <source>Endocr Rev</source> <year>2007</year>; <volume>28</volume>: <fpage>20</fpage>–<lpage>47</lpage>.</citation></ref>
<ref id="bibr48-0300060513476585"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JP</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Perkins</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)</article-title>. <source>Cell</source> <year>1993</year>; <volume>75</volume>: <fpage>59</fpage>–<lpage>72</lpage>.</citation></ref>
<ref id="bibr49-0300060513476585"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laustsen</surname><given-names>PG</given-names></name><name><surname>Russell</surname><given-names>SJ</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function</article-title>. <source>Mol Cell Biol</source> <year>2007</year>; <volume>27</volume>: <fpage>1649</fpage>–<lpage>1664</lpage>.</citation></ref>
<ref id="bibr50-0300060513476585"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakae</surname><given-names>J</given-names></name><name><surname>Kido</surname><given-names>Y</given-names></name><name><surname>Accili</surname><given-names>D</given-names></name></person-group>. <article-title>Distinct and overlapping functions of insulin and IGF-I receptors</article-title>. <source>Endocr Rev</source> <year>2001</year>; <volume>22</volume>: <fpage>818</fpage>–<lpage>835</lpage>.</citation></ref>
<ref id="bibr51-0300060513476585"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>VC</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name><etal/></person-group>. <article-title>The insulin-like growth factor system and its pleiotropic functions in brain</article-title>. <source>Endocr Rev</source> <year>2005</year>; <volume>26</volume>: <fpage>916</fpage>–<lpage>943</lpage>.</citation></ref>
<ref id="bibr52-0300060513476585"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>G</given-names></name></person-group>. <article-title>The complex biology of the receptor for the insulin-like growth factor-1</article-title>. <source>Drug News Perspect</source> <year>2003</year>; <volume>16</volume>: <fpage>525</fpage>–<lpage>531</lpage>.</citation></ref>
<ref id="bibr53-0300060513476585"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pandini</surname><given-names>G</given-names></name><name><surname>Genua</surname><given-names>M</given-names></name><name><surname>Frasca</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway</article-title>. <source>Ann N Y Acad Sci</source> <year>2009</year>; <volume>1155</volume>: <fpage>263</fpage>–<lpage>267</lpage>.</citation></ref>
<ref id="bibr54-0300060513476585"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamimi</surname><given-names>RM</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>128</volume>: <fpage>243</fpage>–<lpage>250</lpage>.</citation></ref>
<ref id="bibr55-0300060513476585"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>HB</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Expression of IGF-1R in colorectal polyps and its role in colorectal carcinogenesis</article-title>. <source>Technol Cancer Res Treat</source> <year>2011</year>; <volume>10</volume>: <fpage>381</fpage>–<lpage>389</lpage>.</citation></ref>
<ref id="bibr56-0300060513476585"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>PN</given-names></name><name><surname>De Armond</surname><given-names>DT</given-names></name><name><surname>Adamo</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2</article-title>. <source>Oncogene</source> <year>2001</year>; <volume>20</volume>: <fpage>8203</fpage>–<lpage>8214</lpage>.</citation></ref>
<ref id="bibr57-0300060513476585"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Jamal</surname><given-names>RT</given-names></name><name><surname>Kivelä</surname><given-names>T</given-names></name></person-group>. <article-title>Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma</article-title>. <source>Can J Ophthalmol</source> <year>2011</year>; <volume>46</volume>: <fpage>471</fpage>–<lpage>476</lpage>.</citation></ref>
<ref id="bibr58-0300060513476585"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>T</given-names></name><name><surname>Seckinger</surname><given-names>A</given-names></name><name><surname>Rème</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Gene expression profiling in multiple myeloma – reporting of entities, risk, and targets in clinical routine</article-title>. <source>Clin Cancer Res</source> <year>2011</year>; <volume>17</volume>: <fpage>7240</fpage>–<lpage>7247</lpage>.</citation></ref>
<ref id="bibr59-0300060513476585"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalra</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell</article-title>. <source>Int J Cancer</source> <year>2012</year>; <volume>131</volume>: <fpage>2143</fpage>–<lpage>2152</lpage>.</citation></ref>
<ref id="bibr60-0300060513476585"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bielen</surname><given-names>A</given-names></name><name><surname>Perryman</surname><given-names>L</given-names></name><name><surname>Box</surname><given-names>GM</given-names></name><etal/></person-group>. <article-title>Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β</article-title>. <source>Mol Cancer Ther</source> <year>2011</year>; <volume>10</volume>: <fpage>1407</fpage>–<lpage>1418</lpage>.</citation></ref>
<ref id="bibr61-0300060513476585"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sachdev</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Fujita-Yamaguchi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer</article-title>. <source>Cancer Res</source> <year>2006</year>; <volume>66</volume>: <fpage>2391</fpage>–<lpage>2402</lpage>.</citation></ref>
<ref id="bibr62-0300060513476585"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schernhammer</surname><given-names>ES</given-names></name><name><surname>Holly</surname><given-names>JM</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II</article-title>. <source>Endocr Relat Cancer</source> <year>2006</year>; <volume>13</volume>: <fpage>583</fpage>–<lpage>592</lpage>.</citation></ref>
<ref id="bibr63-0300060513476585"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valentinis</surname><given-names>B</given-names></name><name><surname>Baserga</surname><given-names>R</given-names></name></person-group>. <article-title>IGF-I receptor signalling in transformation and differentiation</article-title>. <source>Mol Pathol</source> <year>2001</year>; <volume>54</volume>: <fpage>133</fpage>–<lpage>137</lpage>.</citation></ref>
<ref id="bibr64-0300060513476585"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baserga</surname><given-names>R</given-names></name><name><surname>Peruzzi</surname><given-names>F</given-names></name><name><surname>Reiss</surname><given-names>K</given-names></name></person-group>. <article-title>The IGF-1 receptor in cancer biology</article-title>. <source>Int J Cancer</source> <year>2003</year>; <volume>107</volume>: <fpage>873</fpage>–<lpage>877</lpage>.</citation></ref>
<ref id="bibr65-0300060513476585"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedrichs</surname><given-names>N</given-names></name><name><surname>Küchler</surname><given-names>J</given-names></name><name><surname>Endl</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma</article-title>. <source>J Pathol</source> <year>2008</year>; <volume>216</volume>: <fpage>428</fpage>–<lpage>439</lpage>.</citation></ref>
<ref id="bibr66-0300060513476585"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sachdev</surname><given-names>D</given-names></name><name><surname>Hartell</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>AV</given-names></name><etal/></person-group>. <article-title>A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells</article-title>. <source>J Biol Chem</source> <year>2004</year>; <volume>279</volume>: <fpage>5017</fpage>–<lpage>5024</lpage>.</citation></ref>
<ref id="bibr67-0300060513476585"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reinmuth</surname><given-names>N</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer</article-title>. <source>Lab Invest</source> <year>2002</year>; <volume>82</volume>: <fpage>1377</fpage>–<lpage>1389</lpage>.</citation></ref>
<ref id="bibr68-0300060513476585"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Weiss</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo</article-title>. <source>Int J Cancer</source> <year>2003</year>; <volume>107</volume>: <fpage>564</fpage>–<lpage>570</lpage>.</citation></ref>
<ref id="bibr69-0300060513476585"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yee</surname><given-names>D</given-names></name></person-group>. <article-title>Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility</article-title>. <source>Cancer Res</source> <year>2002</year>; <volume>62</volume>: <fpage>4369</fpage>–<lpage>4375</lpage>.</citation></ref>
<ref id="bibr70-0300060513476585"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics</article-title>. <source>Mol Cancer Ther</source> <year>2012</year>; <volume>11</volume>: <fpage>1400</fpage>–<lpage>1410</lpage>.</citation></ref>
<ref id="bibr71-0300060513476585"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goya</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors</article-title>. <source>Cancer Res</source> <year>2004</year>; <volume>64</volume>: <fpage>6252</fpage>–<lpage>6258</lpage>.</citation></ref>
<ref id="bibr72-0300060513476585"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodon</surname><given-names>J</given-names></name><name><surname>DeSantos</surname><given-names>V</given-names></name><name><surname>Ferry</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><etal/></person-group>. <article-title>Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials</article-title>. <source>Mol Cancer Ther</source> <year>2008</year>; <volume>7</volume>: <fpage>2575</fpage>–<lpage>2588</lpage>.</citation></ref>
<ref id="bibr73-0300060513476585"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Girnita</surname><given-names>A</given-names></name><name><surname>Strömberg</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma</article-title>. <source>Neuro Oncol</source> <year>2010</year>; <volume>12</volume>: <fpage>19</fpage>–<lpage>27</lpage>.</citation></ref>
<ref id="bibr74-0300060513476585"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>A</given-names></name><name><surname>Scholar</surname><given-names>EM</given-names></name></person-group>. <article-title>Role of tyrosine kinase inhibitors in cancer therapy</article-title>. <source>J Pharmacol Exp Ther</source> <year>2005</year>; <volume>315</volume>: <fpage>971</fpage>–<lpage>979</lpage>.</citation></ref>
<ref id="bibr75-0300060513476585"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollak</surname><given-names>M</given-names></name></person-group>. <article-title>Insulin, insulin-like growth factors and neoplasia</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source> <year>2008</year>; <volume>22</volume>: <fpage>625</fpage>–<lpage>638</lpage>.</citation></ref>
<ref id="bibr76-0300060513476585"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Höpfner</surname><given-names>M</given-names></name><name><surname>Baradari</surname><given-names>V</given-names></name><name><surname>Huether</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours</article-title>. <source>Endocr Relat Cancer</source> <year>2006</year>; <volume>13</volume>: <fpage>135</fpage>–<lpage>149</lpage>.</citation></ref>
<ref id="bibr77-0300060513476585"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slomiany</surname><given-names>MG</given-names></name><name><surname>Black</surname><given-names>LA</given-names></name><name><surname>Kibbey</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma</article-title>. <source>Cancer Lett</source> <year>2007</year>; <volume>248</volume>: <fpage>269</fpage>–<lpage>279</lpage>.</citation></ref>
<ref id="bibr78-0300060513476585"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>García-Echeverría</surname><given-names>C</given-names></name><name><surname>Pearson</surname><given-names>MA</given-names></name><name><surname>Marti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>In vivo antitumor activity of NVP-AEW541 – a novel, potent, and selective inhibitor of the IGF-IR kinase</article-title>. <source>Cancer Cell</source> <year>2004</year>; <volume>5</volume>: <fpage>231</fpage>–<lpage>239</lpage>.</citation></ref>
<ref id="bibr79-0300060513476585"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scotlandi</surname><given-names>K</given-names></name><name><surname>Manara</surname><given-names>MC</given-names></name><name><surname>Nicoletti</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors</article-title>. <source>Cancer Res</source> <year>2005</year>; <volume>65</volume>: <fpage>3868</fpage>–<lpage>3876</lpage>.</citation></ref>
<ref id="bibr80-0300060513476585"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Höpfner</surname><given-names>M</given-names></name><name><surname>Huether</surname><given-names>A</given-names></name><name><surname>Sutter</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells</article-title>. <source>Biochem Pharmacol</source> <year>2006</year>; <volume>71</volume>: <fpage>1435</fpage>–<lpage>1448</lpage>.</citation></ref>
<ref id="bibr81-0300060513476585"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitson</surname><given-names>BA</given-names></name><name><surname>Jacobson</surname><given-names>BA</given-names></name><name><surname>Frizelle</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award</article-title>. <source>Ann Thorac Surg</source> <year>2006</year>; <volume>82</volume>: <fpage>996</fpage>–<lpage>1002</lpage>.</citation></ref>
<ref id="bibr82-0300060513476585"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Höpfner</surname><given-names>M</given-names></name><name><surname>Sutter</surname><given-names>AP</given-names></name><name><surname>Huether</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer</article-title>. <source>World J Gastroenterol</source> <year>2006</year>; <volume>12</volume>: <fpage>5635</fpage>–<lpage>5643</lpage>.</citation></ref>
<ref id="bibr83-0300060513476585"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanno</surname><given-names>B</given-names></name><name><surname>Mancini</surname><given-names>C</given-names></name><name><surname>Vitali</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Clin Cancer Res</source> <year>2006</year>; <volume>12</volume>: <fpage>6772</fpage>–<lpage>6780</lpage>.</citation></ref>
<ref id="bibr84-0300060513476585"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manara</surname><given-names>MC</given-names></name><name><surname>Landuzzi</surname><given-names>L</given-names></name><name><surname>Nanni</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Preclinical <italic>in vivo</italic> study of new insulin-like growth factor-I receptor–specific inhibitor in Ewing's sarcoma</article-title>. <source>Clin Cancer Res</source> <year>2007</year>; <volume>13</volume>: <fpage>1322</fpage>–<lpage>1330</lpage>.</citation></ref>
<ref id="bibr85-0300060513476585"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maiso</surname><given-names>P</given-names></name><name><surname>Ocio</surname><given-names>EM</given-names></name><name><surname>Garayoa</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells</article-title>. <source>Br J Haematol</source> <year>2008</year>; <volume>141</volume>: <fpage>470</fpage>–<lpage>482</lpage>.</citation></ref>
<ref id="bibr86-0300060513476585"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moser</surname><given-names>C</given-names></name><name><surname>Schachtschneider</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis</article-title>. <source>Eur J Cancer</source> <year>2008</year>; <volume>44</volume>: <fpage>1577</fpage>–<lpage>1586</lpage>.</citation></ref>
<ref id="bibr87-0300060513476585"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarn</surname><given-names>C</given-names></name><name><surname>Rink</surname><given-names>L</given-names></name><name><surname>Merkel</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors</article-title>. <source>Proc Natl Acad Sci USA</source> <year>2008</year>; <volume>105</volume>: <fpage>8387</fpage>–<lpage>8392</lpage>.</citation></ref>
<ref id="bibr88-0300060513476585"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas</article-title>. <source>Mol Cancer Ther</source> <year>2008</year>; <volume>7</volume>: <fpage>1483</fpage>–<lpage>1493</lpage>.</citation></ref>
<ref id="bibr89-0300060513476585"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lisztwan</surname><given-names>J</given-names></name><name><surname>Pornon</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in <italic>in vitro</italic> models of estrogen-dependent breast cancer</article-title>. <source>Breast Cancer Res</source> <year>2008</year>; <volume>10</volume>: <fpage>R56</fpage>–<lpage>R56</lpage>.</citation></ref>
<ref id="bibr90-0300060513476585"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girnita</surname><given-names>A</given-names></name><name><surname>Girnita</surname><given-names>L</given-names></name><name><surname>Del Prete</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth</article-title>. <source>Cancer Res</source> <year>2004</year>; <volume>64</volume>: <fpage>236</fpage>–<lpage>242</lpage>.</citation></ref>
<ref id="bibr91-0300060513476585"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasilcanu</surname><given-names>D</given-names></name><name><surname>Girnita</surname><given-names>A</given-names></name><name><surname>Girnita</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway</article-title>. <source>Oncogene</source> <year>2004</year>; <volume>23</volume>: <fpage>7854</fpage>–<lpage>7862</lpage>.</citation></ref>
<ref id="bibr92-0300060513476585"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>QS</given-names></name><name><surname>Mulvihill</surname><given-names>MJ</given-names></name><name><surname>Rosenfeld-Franklin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling <italic>in vitro</italic> and inhibits insulin-like growth factor-I receptor–dependent tumor growth <italic>in vivo</italic></article-title>. <source>Mol Cancer Ther</source> <year>2007</year>; <volume>6</volume>: <fpage>2158</fpage>–<lpage>2167</lpage>.</citation></ref>
</ref-list>
</back>
</article>